Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Edrophonium is a short-acting, reversible acetylcholinesterase inhibitor used in veterinary medicine primarily for diagnostic and neuromuscular applications in dogs and cats.
It produces a rapid but brief increase in acetylcholine activity, making it especially useful in conditions requiring immediate assessment of neuromuscular function.
The drug has a fast onset of action — effects on skeletal muscle within about one minute after intravenous administration — and a short duration of effect, persisting up to 10 minutes . Myasthenic patients may have effects persisting longer after the first dose.
This rapid and transient activity makes edrophonium particularly valuable for diagnostic testing rather than long-term therapeutic use.
Mechanism of Action (MOA): Edrophonium competitively inhibits acetylcholinesterase at the neuromuscular junction, preventing the breakdown of acetylcholine and thereby enhancing cholinergic transmission.
This results in improved neuromuscular signal conduction and temporary reversal of muscle weakness in disorders such as myasthenia gravis.
Indications
Edrophonium is primarily used in dogs and cats for diagnostic evaluation of neuromuscular disorders and for short-term modulation of cardiac or neuromuscular function. Its rapid onset and very short duration make it particularly suitable for situations requiring immediate but transient effects.
-
Diagnosis of myasthenia gravis:
Used as a rapid diagnostic test to differentiate myasthenia gravis from other causes of exercise intolerance or generalized weakness. A transient improvement in muscle strength following administration supports the diagnosis. -
Assessment of treatment response in myasthenia gravis:
Helps distinguish between under-treatment and over-treatment with longer-acting anticholinesterases. Improvement in strength suggests inadequate therapy, while worsening weakness indicates possible overdosage. - Supraventricular tachycardia:
Supraventrical tachycardia : May be used in a controlled intensive care setting for short-term control of supraventricular tachycardia through vagal stimulation, only when other traditional antiarrhythmics have been ineffective. -
Reversal of non-depolarizing neuromuscular blockade:
Administered to antagonize non-depolarizing neuromuscular blocking agents during recovery from anesthesia, typically in combination with atropine to reduce muscarinic side effects. Note: due to its short duration, neostigmine or pyridostigmine may be more useful.
Dosage (Reference)
Dog
In dogs, edrophonium is used intravenously for diagnostic and short-term therapeutic purposes due to its very rapid onset and short duration of action. Clinical response is typically observed within seconds and lasts only a few minutes.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| Diagnosis of myasthenia gravis | IV | 0.1–0.2 mg/kg (maximum 5 mg/dog) — start with 0.1 mg/kg, escalate to 0.2 mg/kg if no response after 60 seconds. | — | Improvement within 30 sec; effect lasts ~5 min. If no response, repeat after 10–20 min using 0.2 mg/kg. |
| Reversal of non-depolarizing neuromuscular blockage | IV | 0.25–0.5 mg/kg IV — start with the lower dose; repeat if necessary. | — | Administer with atropine 0.02–0.04 mg/kg IV immediately before edrophonium; ensure spontaneous recovery from NMB has begun before reversal. |
• Atropine (0.02–0.04 mg/kg IV) should be drawn up and immediately available before injection to control cholinergic side effects (salivation, lacrimation, urination, defecation, GI distress, emesis — the ‘SLUDGE’ signs).
• Positive myasthenia gravis test: rapid improvement within 30 seconds with short-lived effect (~5 minutes).
• Ensure ventilatory support when reversing neuromuscular blockade until full respiratory function returns.
• Administer IV doses carefully and monitor for bradycardia and cholinergic effects.
Cat
In cats, edrophonium is primarily used for the diagnosis of myasthenia gravis. Due to increased sensitivity to cholinergic effects, careful dosing and monitoring are required.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| Diagnosis of myasthenia gravis | IV | 0.25–0.5 mg/cat (total dose) | — | Improvement within 30 sec; effect lasts ~5 min. |
• Atropine (0.02–0.04 mg/kg IV) should be drawn up and immediately available before injection — cats are especially sensitive to cholinergic effects.
• Positive response: rapid improvement within 30 seconds with short duration (~5 minutes).
• Doses substantially higher than the diagnostic range can cause bradycardia and cholinergic crisis. The diagnostic range (0.25–0.5 mg/cat) is sufficient.
• Monitor closely for bradycardia and cholinergic signs.
Warnings & Precautions
Edrophonium is a rapid-acting cholinesterase inhibitor with potent cholinergic effects. Careful patient selection, dose control, and close monitoring are essential to avoid adverse cardiovascular and respiratory complications.
- Bronchial disease: Use with caution in patients with respiratory disease, particularly feline asthma, due to increased risk of bronchoconstriction from cholinergic stimulation.
- Cardiac disease: Use cautiously in patients with bradycardia or other cardiac arrhythmias, as vagal effects may exacerbate conduction disturbances.
- Hypotension: May worsen existing hypotension due to parasympathetic effects; monitor cardiovascular status closely.
- Renal impairment: Use with caution in patients with significant renal impairment
- Epilepsy: Edrophonium does not cross the blood-brain barrier well (quaternary ammonium). Use general caution in any patient with significant comorbid disease.
- Availability of atropine: Atropine should always be readily available during administration to counteract excessive muscarinic (cholinergic) effects.
- Diagnostic use limitation: Due to its very short duration of action, edrophonium is primarily useful for diagnostic or short-term purposes rather than sustained therapy.
- Edrophonium may no longer be commercially manufactured and no commercially available dosage forms could be located. Verify availability with a compounding pharmacy before prescribing. Preferred alternative when unavailable: neostigmine methylsulfate 40 mcg/kg IM or 20 mcg/kg IV.
- Atropine caution: while atropine prevents or treats muscarinic side effects, it can also mask the early clinical signs of cholinergic crisis . Do not rely solely on absence of muscarinic signs to confirm patient safety — monitor heart rate and respiratory effort directly.
Drug Interactions
Clinically significant drug interactions with edrophonium are primarily related to its effects on neuromuscular transmission. Care should be taken when combining it with agents that influence neuromuscular blockade.
- Depolarizing neuromuscular blocking agents (e.g. suxamethonium): Concurrent use at higher doses may potentiate neuromuscular blockade and prolong paralysis; avoid combination or use with extreme caution.
- Digoxin: edrophonium’s cardiac effects may be increased in patients receiving digoxin — excessive slowing of heart rate may occur. Monitor heart rate closely.
- Dexpanthenol: theoretical additive cholinergic effects when used with edrophonium.
- Non-depolarizing NMB agents (pancuronium, tubocurarine, gallamine, vecuronium, atracurium, cisatracurium, rocuronium): edrophonium antagonizes their actions — this is the basis for using edrophonium for NMB reversal at end of anaesthesia (with concurrent atropine).
Side Effects & Overdose
Side Effects
Adverse effects of edrophonium are primarily related to its cholinergic (muscarinic) activity and are usually transient due to its short duration of action.
- Gastrointestinal effects: Nausea, vomiting, and diarrhoea may occur.
- Increased salivation: Common due to muscarinic stimulation.
- Full cholinergic side-effect profile (SLUDGE): Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis. Also: bradycardia, sinus arrest, bronchospasm — risk increases without atropine pretreatment. Most effects are mild and resolve quickly given the drug’s short duration.
Overdose
Overdosage of edrophonium results in excessive cholinergic stimulation and neuromuscular dysfunction, which may lead to serious complications if not promptly managed.
- Muscle effects: Muscle fasciculations followed by weakness or paralysis.
- Cardiovascular effects: Severe bradyarrhythmias, including possible asystole, especially if used without atropine during neuromuscular blockade reversal.
- Management: Provide respiratory support and administer atropine intravenously to counteract muscarinic effects.
Key Notes
Practical clinical points to optimize the safe and effective use of edrophonium in dogs and cats:
- Rapid diagnostic value: The extremely fast onset and short duration make edrophonium ideal for real-time assessment of neuromuscular function during clinical examination.
- Short duration advantage: Transient effects allow quick differentiation of neuromuscular disorders without prolonged drug influence on patient status.
- Monitoring during administration: Continuous observation is essential during IV use due to the rapid onset of effects and potential for abrupt clinical changes.
- Use when immediate response is needed: Particularly useful in situations where a rapid, reversible effect is preferred over longer-acting anticholinesterases.
- Alternative option: If edrophonium is unavailable, neostigmine may be used as an alternative diagnostic agent, although with a slower onset and longer duration.
